New York Times, December 6, 2018
Katie Thomas

Links

Read the Full Article

The drug maker Actelion Pharmaceuticals has agreed to a $360 million settlement stemming from an investigation into whether the company illegally funneled kickbacks through a patient-assistance charity, federal prosecutors said Thursday.

Actelion, which was acquired by Johnson & Johnson in 2017 and makes expensive drugs to treat a rare lung condition, is the latest pharmaceutical company to settle federal inquiries into their ties to patient-assistance groups, including whether companies have used the patient programs to increase the price of their drugs. [...]

health care costs health law policy pharmaceuticals regulation